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INTRODUCTION 
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                                                     INTRODUCTION 
 
Glucocorticoid (GC) are produced by the adrenal cortex, under the 
direction of  hypothalamic-pituitary-adrenal axis. They are crutial for 
glucose,  lipid and protein metabolism and therefore for energy balance.  
At supraphysiological concentrations  ie. > 10 mg/ day as that is  
their normal daily rate of secretion, GCs will exhibit their anti- 
inflammatory   action and so used for treating a wide array of 
inflammatory and (AI)    autoimmune conditions. 
These include exacerbations of chronic obstructive pulmonary   
disease (COPD), a clinical manifestation of an acute-on-chronic 
inflammatory  process in the airways, often  with systemic spillover.  
Inspite of their enormous useful actions, usage of  corticosteroid is  under 
limitation in view of their side effect profile, which in turn is dependent on  
amount of drug and duration for which the drug was administered for the 
sake of  treatment. 
Side effects of steroids are mainly metabolic derangements, 
including the development of central adiposity, hepatic steatosis, 
dyslipidaemia  characterised  by increased plasma levels of triglyceride 
rich lipoproteins (TRL)  and nonesterified fatty acids (NEFA), increased 
breakdown of skeletal muscle mass, insulin resistance, glucose intolerance 
and overt diabetes in susceptible individuals.  
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The combination of  hypertension, central obesity and glucose  
Intolerance  is called as `Reaven's Syndrome X’ or the ‘Metabolic 
Syndrome’. 
The most common adverse effect following steroid therapy is the    
development of hyper (dys) glycemia.  
Hyperglycemia is an independent predictor of increased mortality in 
hospitalized patients with a range of comorbidities, including an  
exacerbation of COPD.  
By opposing the actions of insulin, glucocorticoids could contribute 
to insulin resistance and its association with other cardiovascular risk 
factors. 
Endogenous glucocorticoid excess in Cushing’s syndrome 
predominantly increases postprandial blood glucose concentration with 
fasting  glucose often in the normal range. If exogenous glucocorticoids 
cause a similar pattern of hyperglycemia, current conventional strategies 
may inadequately treat  postprandial hyperglycemia, and use of long-acting 
basal insulin may precipitate nocturnal hypoglycemia. Avoidance of 
hypoglycemia is important because it has been implicated as a potential 
cause of increased mortality in patients receiving intensive insulin therapy.  
Studies showed that the glycemic rise related to steroid therapy 
usually begins 4 hours after the dose and usually persists for up to 16 
hours.  
  
3 
 
Therefore, conventional testing methods to diagnose diabetes may 
not be appropriate in steroid-induced diabetes. Fasting hyperglycemia may 
not be evident in many cases and only postprandial hyperglycemia is seen 
in most patients. So it is hypothesized that prednisolone causes substantial 
hyperglycemia, predominantly in the postprandial period. A better 
understanding of the glycemic effect of prednisolone will allow the 
development of a specific treatment strategy for prednisolone-induced 
hyperglycemia that targets the time of day during which hyperglycemia 
predominates. 
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ADRENAL CORTEX  
Adrenal cortex based on  histology and function are separated into 
three areas that produce various hormones under different specific 
regulatory influences.                                                                                                                                
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DHEAS circulates at levels 1000 times higher than DHEA. DHEAS 
are converted to DHEA in the periphery by DHEA sulfatase.      
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The inner zones in the adrenal cortex – consisting cells of zona 
fasciculata & zona reticularis goes for atrophy in the absence of the 
anterior pituitary. So the production of glucocorticoids and adrenal 
androgens will get markedly impaired. 
Persistently high levels of ACTH, due to either repeated 
administration of higher doses of ACTH (exogenously) or to excessive 
endogenous ACTH production will lead on to hypertrophy and hyperplasia 
of the inner zones - consisting cells of  zona fasciculata & zona reticularis  
of the adrenal cortex resulting in overproduction of cortisol and adrenal 
androgens. 
Adrenal hyperplasia is most common with congenital disorders 
affecting steroidogenesis.  In Congenital Adrenal Hyperplasia, ACTH 
levels are persistently elevated as a secondary response to impaired cortisol 
production from adrenal cortex.  
There are newer informations coming up comparing the relative 
roles of ACTH & other POMC-derived peptides in stimulating adrenal 
growth. Yet the essential role of  anterior pituitary in maintaining the 
integrity of the zona fasciculata of adrenal cortex is indisputable. 
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STEROID SYNTHESIS 
 Mixed-function oxidases is the one that is commonly associated 
with steroid generation. They also play important roles in metabolism of 
xenobiotics that include drugs and environmental pollutants, and also in 
the synthesis of endogenous compounds like vitamin D, bile acids, fatty 
acids, prostaglandins, and biogenic amines apart from steroid hormone.
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PHYSIOLOGY OF STEROID 
Corticosteroids have widespread effects, that include changes in 
carbohydrate, protein, & lipid breakdown; maintenance of electrolyte & 
fluid balance; and preservation of normal functioning of the kidney, 
skeletal muscle, endocrine, nervous, cardiovascular & the immune system. 
In addition to all the above mentioned items, corticosteroids make 
the organism to be endowed with the capacity to resist  stressful 
circumstances like noxious stimuli and environmental changes. 
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Sometimes the action of corticosteroids are related to the presence 
of other hormones. For eg, in the absence of lipolytic hormones, cortisol 
has clearly no effect on the fastness with which lipid breakdown occurs in 
adipocytes. In a similar way, in the absence of corticosteroid 
(glucocorticoids), norepinephrine and epinephrine have only minimal 
effects on lipid breakdown. So administration of a small dose of 
glucocorticoid markedly increases the lipid degradation action of these 
catecholamines. These effects of corticosteroids that need concerted 
actions with other hormonal regulators are called permissive.     
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MECHANISM OF ACTION OF CORTICOSTEROID 
Corticosteroids  controls the expression of corticosteroid-responsive 
genes in target tissue by binding to particular receptor  proteins in the 
target tissues thereby resulting in changes in the levels of proteins 
produced by the different target tissues.  
As longer time - required to modulate (transcription) gene 
expression and (translation) protein synthesis, actions of steroid appear late 
after its administration.  
Though corticosteroids most of the time act by increasing gene 
transcription, there are proven examples in which (cortisol) glucocorticoids 
reduce gene transcription. Eg. Pro-opiomelanocortin gene, 
cyclooxygenase-2 (COX-2) gene, inducible nitric oxide synthase (NOS2) 
gene.     
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This fact suggests that selective GR ligands will have anti-
inflammatory actions with very less metabolic side effects. 
In addition to the above mentioned different modes of action, 
steroids may  produce some of their immediate action by non- genomic 
mechanism. 
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Steroid activates GR (glucocorticoid receptor) and translocates into 
the   nucleus. The translocated GR is now complexed with proteins like 
(HSP) heat-   shock protein 90; HSP70; and  immunophilin (56,000-Da 
protein that bind the   immunosuppressive drugs- cyclosporine and 
tacrolimus).  
GR has 2 isoforms alpha & beta. 
GR beta is a truncated dominantly negative variant which lacks 
around 35   amino acids at its C-terminus and so unable to bind 
glucocorticoids or induce   gene expression. 
GR beta expression is increased by tumor necrosis factor (TNF) and 
some   other pro-inflammatory cytokines. So its increased level is thought 
to contribute   to glucocorticoid resistance in some individuals. 
In the case of partial loss of GR function, the HPA axis is reset to a   
higher level so as to produce compensatory increase in ACTH and cortisol    
secretion. This excess ACTH production increases mineralocorticoids and 
sex    hormone production in addition to corticosteroid. Because the 
androgen receptor & mineralocorticoid receptor are intact, these persons 
present with features of    mineralocorticoid excess (hypokalemic 
metabolic alkalosis & hypertension) with   or without androgen level 
excess (menstrual irregularities, anovulation,   infertility, acne, hirsutism, 
male pattern baldness). In the pediatric age group, the   excess adrenal 
androgens will result in precocious sexual development.  
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Non-Receptor  Mediated Mechanism for Corticosteroid Specificity 
The (11betaHSD2) type 2 isozyme of 11beta-hydroxysteroid    
dehydrogenase plays an important role in steroid specificity especially in 
kidney,    colon & salivary glands.  
This enzyme converts glucocorticoids such as cortisol to cortisone 
which is receptor-inactive 11-keto derivative. As aldosterone exist in 
hemiacetal form which is its major form in the physiological setting - it is  
resistant to 11beta HSD action. Thus mineralocorticoid escapes this 
inactivation  and maintains its sodium & water retention activity.  
In the absence of 11betaHSD2, as take place in the syndrome of 
apparent mineralocorticoid excess (an inherited disease), the 
Mineralocorticoid Receptor is activated by cortisol, leading on to severe 
hypokalemia and hypertension.  
A state of aldosterone excess also can be produced by  inhibiting 
11betaHSD with glycyrrhizic acid (a component of licorice) which is the 
cause of licorice-induced hypertension. 
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ROLE OF STEROIDS 
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Steroid reduces glucose uptake in thymocytes, polymorphonuclear   
leukocyte, adipose tissue, skin, fibroblasts. These action occur probably 
due to   translocating the glucose transporters from the plasma membrane 
of these target tissue to an intracellular location. These peripheral actions 
of steroid are  also associated with a number of other catabolic effects like 
negative nitrogen   balance, thinning of the skin, atrophy of lymphoid 
tissue & decreased muscle   mass. 
 
.  
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One reason for the redistribution of body fat is due to the difference 
in insulin & glucocorticoid sensitivity in peripheral and truncal  
adipocytes.  
So truncal adipocytes respond mainly to increased levels of insulin 
which gets secreted in response to glucocorticoid-induced hyperglycemia, 
at the same time peripheral adipocytes are very less sensitive to insulin but 
respond well to the glucocorticoid-facilitated effects of other lipolytic  
hormones (growth hormone, catecholamines).  
This differential sensitivity of steroids & other hormone may reflect 
differences in the expression of  enzyme 11betaHSD1 which is responsible 
for converting cortisone (inactive form) into cortisol ( active form) in 
target tissues. 
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Anti-Inflammatory and Immunosuppressive Effects 
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CELL TYPE 
Macrophages 
and 
monocytes 
FACTOR 
Arachidonic 
acid and its 
metabolites 
(prostaglandins 
and 
leukotrienes) 
Cytokines, 
including: 
interleukin (IL)-
1, IL-6, and 
tumor necrosis 
factor (TNF) 
Acute phase 
reactants 
COMMENTS 
Mediated by 
glucocorticoid 
inhibition of 
COX-2 and 
PLA2 
Production and 
release are 
blocked. The 
cytokines exert 
multiple effects 
on inflammation 
(e.g., activation 
of T cells, 
stimulation of 
fibroblast 
proliferation). 
These include 
the third 
component of 
complement. 
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GLUCOCORTICOID & INSULIN RESISTANCE 
The  ‘Metabolic Syndrome’ or  ‘Reaven's Syndrome X' [1]   or  
‘Insulin Resistance Syndrome' consists of hypertension, glucose 
intolerance   and dyslipidaemia which is further associated with low birth 
weight [2,3],  central obesity [4],  abnormalities of thrombosis and 
fibrinolysis, impaired   endothelium-dependent vasodilatation [5], 
reproductive dysfunction in women  [6] and insulin resistance. All these 
are risk factors for cardiovascular disease. 
          Cortisol deficiency consists of postural hypotension, weight loss and 
hypoglycaemia. While cortisol excess comprises of    hypertension, central 
obesity and glucose intolerance. Opposing the insulin action, i.e. producing 
a insulin resistance state is one of the main mechanism by  which the 
above mentioned effects of cortisol excess occur. 
Insulin is produced by beta part in response to increase  in plasma 
glucose levels, specific amino acids like arginine, electrolyte- potassium 
and parasympathetic nervous system tone. 
Insulin resistance indicate  either impaired insulin- directed decrease 
of hepatic glucose production and or impaired insulin-dependent rise in 
peripheral glucose uptake. Enhanced hepatic glucose release    may be 
most important in subjects with glucose intolerance [9] whereas impaired 
peripheral glucose uptake may be the major defect in subjects with normal 
glucose tolerance [10].                                                                                                                                                                                     
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           Steroid by opposing the action of insulin, increase central appetite 
[16].  
Glucocorticoids inhibit insulin production from pancreatic beta-cells 
[17,19].   
Central actions of Glucocorticoids may result in  enhanced vagal 
stimulation of insulin secretion. 
TARGET ORGAN RESPONSES TO INSULIN 
Glucocorticoids can decrease insulin receptor binding affinity 
without decreasing insulin receptor numbers [22,23], decrease receptor    
number and affinity [24], have no effect on receptor affinity or number 
[25] or    increase receptor number without affecting affinity [15].  
These are the various things observed with usage of steroid. 
It is now obvious to conclude that these small changes in insulin 
receptor number or binding affinity are not sufficient  enough to explain 
the degree of insulin resistance seen with glucocorticoids.  
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TISSUE-SPECIFIC DETERMINANTS FOR INSULIN RESPONSE 
  
  
40 
 
In adipocytes, lipid synthesis pathways occurs predominantly.  
In skeletal muscle either glycogen synthesis or oxidative    
metabolism (of pyruvate or free fatty acids) occurs predominantly. 
GLUT 4 is expressed especially in skeletal muscle and    lipoprotein 
lipase mainly in adipose tissue. 
Actions of glucocorticoids (grey arrows) and insulin (striped arrows) 
are shown either as positive (arrow up) or negative (arrow down)  effects 
in the above mentioned diagram. 
The major action of glucocorticoids is to reduce insulin-    mediated 
vasodilatation, enhance lipolysis especially by its permissive effect ( ie    
by inducing local production of adrenaline), thus resulting in increased free 
fatty  acid level in serum which competes with pyruvate for mitochondrial 
oxidative metabolism & reduce translocation of GLUT 4 to the cell 
surface. 
So the expression of GLUT 4 is actually increased by    
glucocorticoids in skeletal muscle and adipose tissue in a similar way by 
which    insulin does. However, translocation of GLUT 4 to the cell surface 
in response   to the insulin and to other stimuli (e.g. hypoxia) is inhibited in 
the presence of     glucocorticoids [29-33].  
Thus it is made clear that oxidation of pyruvate is affected    by 
competing substrates like non-esterified free fatty acids. Acute and not the    
chronic administration of free fatty acids results in insulin resistance. So     
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Acipimox and nicotinic acid administration lowers free fatty acid level 
thereby     increasing insulin sensitivity [35].  
Now we also know that the marked lipolysis caused by     
glucocorticoids is by up-regulation of phenyl-ethanolamine N-
methyltransferase [41], which converts noradrenaline into adrenaline 
especially in skeletal muscle. So inhibition of this enzyme brings down  
glucocorticoid-induced insulin resistance [41]. 
It is also said that, up-regulation of peroxisome proliferator-
activated gamma receptors increases lipolysis. So insulin sensitizing 
thiazolidinediones are exogenous ligands that can be used in case of  
insulin resistance as it down regulates PPAR-gamma[42]. 
Glucocorticoids may result in rise in circulating free  fatty acids by 
inhibiting lipoprotein lipase [43]. 
Non-metabolic determinants of peripheral glucose uptake 
Insulin results in endothelium-dependent vasodilatation by 
increasing nitric oxide synthesis [44] thereby contributing to enhanced 
glucose uptake especially in skeletal muscle. 
The impaired endothelium-dependent vasodilatation in persons with 
features of the metabolic syndrome results in reduced insulin action in 
skeletal muscle. 
Glucocorticoids  affects endothelium-dependent vasodilatation in humans 
in vivo [48] and thus insulin action is counterbalanced by them. 
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Hepatic glucose release 
In some areas insulin and glucocorticoids oppose each other's 
actions, particularly on gluconeogenesis (PEPCK) and release of  glucose 
from glucose 6-phosphate. In other areas, insulin and glucocorticoids  do 
not oppose each other, especially in promoting oxidative glycolysis and 
increasing turnover between glucose 6-phosphate and glycogen. 
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AIM AND OBJECTIVES 
 
1) To study the occurrence of hyperglycemia within 48 hours in 
  patients started on corticosteroid therapy.  
2) To study the various factors associated with steroid induced 
  hyperglycemia with special reference to the :-  
a) nature of corticosteroid used.  
b) presence of risk factors for diabetes. 
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Case Definition:- 
 
       Known Bronchial Asthma or Chronic Obstructive Pulmonary 
Disease patient aged >= 18 years, non- diabetic, on oral drugs like 
salbutamol  and theophylline and not on any oral / inhalational 
steroid so far and not received any parenteral steroid in last 4 weeks 
admitted for acute exacerbation but not in respiratory failure (signs 
include cyanosis, altered mental status with spo2 < 90, heart rate < 
60/ minute, systolic blood pressure < 90 mmHg) are taken as cases 
Material and Method:-  
     Study design:-   Longitudinal Descriptive study 
     Study period:-   6 months 
     Study area:-      Govt. Royapettah Hospital attached to  
                              Govt. Kilpauk Medical College 
                              Chennai. 
Study Population:-  
 
Known Bronchial Asthma or Chronic Obstructive 
Pulmonary  Disease patient aged >= 18 years, non- diabetic, on 
oral drugs like salbutamol and theophylline and not on any oral /  
inhalational steroid   so far and not received any parenteral 
  
45 
 
steroid in last 4 weeks admitted for acute exacerbation but not in 
respiratory failure initiated on steroid therapy at Govt. 
Royapettah hospital attached to Govt. Kilpauk Medical College, 
Chennai. 
Sample Size:-  
Estimated prevalence of steroid induced hyperglycemia is 65% 
      With a precision of 10 
      Sample size is   1.96 x 1.96 x 65 x 35  = 87 
                                    10 x 10 
      With a 10 % margin, Sample size = 100. 
 
Inclusion criteria:- 
 
 Known Bronchial Asthma or Chronic Obstructive 
Pulmonary Disease patient aged >= 18 years, non- diabetic, on 
oral drugs like salbutamol and theophylline and not on any oral /  
inhalational steroid so far and not received any parenteral steroid 
in last 4 weeks admitted for acute exacerbation but not in 
respiratory failure who are to be initiated on steroid therapy. 
  
 
 
 
 
 
 
METHODOLOGY 
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Exclusion Criteria:- 
 
- Known diabetes 
 
- RBS 140-199 mg/dl with HbA1c >= 6.5 
 
- Patient who received  parentral steroids in last 4 weeks 
 
- Patient on IV drip containing dextrose 
 
- Patient in respiratory failure on mechanical ventilation / 
moribund state in need of iv fluid containing dextrose 
 
- Patient on oral steroid ( ex. Very severe persistent asthma 
patient on oral corticosteroid treatment 
 
- Pregnant or lactating female 
 
- Age < 18 years 
 
Methodology:- 
Known Bronchial Asthma or Chronic Obstructive 
Pulmonary Disease patient aged >= 18 years, non- diabetic, on 
oral drugs like salbutamol and theophylline and not on any oral /  
inhalational steroid so far and not received any parenteral steroid 
in last 4 weeks admitted for acute exacerbation but not in 
respiratory failure are taken into the  study. 
 
  
47 
 
Patients to be initiated on steroid therapy - parenteral –  
hydrocortisone / dexamethasone (or) oral - prednisolone in 
standard  doses as demanded by the clinical setting. So patients 
will be substratified depending on the type and dose of steroid 
used. 
Doses of Steroids used in the study are INJECTION 
HYDROCORTISONE – 100 mg 8th hourly, INJECTION 
EXAMETHASONE – 4 mg 12th hourly, TABLET 
PREDNISOLONE 5 mg – 4 tablets 12th hourly. 
Capillary blood glucose (CBG) level of each patient at the 
time of  admission (pre therapy) will be checked with the help of 
glucometer   (ACCU – CHEK active ) 
2 ml of blood will be collected from each patient at the time 
of admission (pre therapy) and sent for  HbA1c 
Again CBG level of each patient at 6, 12, 48 hours after 
initiation of steroid therapy is checked and noted. 
2 ml of blood for doing fasting lipid profile will also be sent 
to biochemistry lab, Govt. Royapettah hospital for processing.   
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Outcomes to be Studied:  
 
Incidence of steroid induced hyperglycemia (CBG >= 200) 
Is Parenteral corticosteroid having more propensity to cause    
hyperglycemia than oral corticosteroid ? 
The time period at which hyperglycemia is more common    
after the administration of steroid (so that antihyperglycemic 
drugs can be targeted at the right time as hyperglycemia is an 
independent cardiovascular risk factor).  
Association between risk factors like obesity, dyslipidemia, 
hypertension and steroid induced hyperglycemia 
 
DEFINITION: 
 
 
-BMI- ( body mass index ) = Weight in kg / Height in sq.m 
 
-BMI     >25 – 30 is overweight,    > 30 kg/sq.m is obese 
 
-WAIST CIRCUMFERENCE –  
 
The bottom edge of measuring tape alligned with the top of 
the hip bone at the side of the waist, then measurement taken by 
wrapping the tape all the way around the waist. 
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Waist circumference < 90 cm in male, < 80 cm in female is normal 
DYSLIPIDEMIA - (by IDF criteria)  
-Fasting triglyceride  > 150, 
-HDL cholesterol < 40 in male &< 50 in female 
HYPERTENSION as defined by JNC 7 
DIABETES MELLITUS  
as defined by American diabetes association  
RBS- 200 / FBS- 126 /  
HbA1C- >6.5% / 2hr PPBS- 200 mg/dl 
 
 
 
  
 
 
 
 
 
 
OBSERVATIONS AND 
RESULTS 
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OBSERVATIONS AND RESULTS 
 
The sample size in our study is 100 patients.  
These patients fell into either one of the two classes which 
are bronchial asthma and chronic obstructive pulmonary disease. 
All the patients met with our inclusion criteria.  
They were administered one among the following three 
steroids namely Hydrocortisone, Dexamethasone & Prednisolone 
for their acute exacerbation.  
Dose of Hydrocortisone being 100 mg iv tds. 
Dose of Dexamethasone being 4 mg iv bd 
Dose of Prednisolone being 5 mg 4 – 0 – 4 (oral). 
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We have concluded the following: 
 
1. Number of patients allotted to each drug category 
 
STEROID USED (dhp) * SEX Crosstabulation 
  
SEX 
Total 
F M 
STEROID 
USED (dhp) 
D 
Count 9 29 38 
% within STEROID 
USED (dhp) 23.7% 76.3% 100.0% 
H 
Count 13 25 38 
% within STEROID 
USED (dhp) 34.2% 65.8% 100.0% 
P 
Count 11 13 24 
% within STEROID 
USED (dhp) 45.8% 54.2% 100.0% 
Total 
Count 33 67 100 
% within STEROID 
USED (dhp) 33.0% 67.0% 100.0% 
Out of 100 patients in our study,  
                          -38% were given Hydrocortisone, 
                          -38% were given Dexamethasone and  
                          -24% were given Prednisolone. 
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2. Gender in each Drug 
 
 
 Female Male Gender Distribution 
D 9 29 Female 33 
H 13 25 Male 67 
P 11 13   
 
 
 
 
 
 
  
Female 
33% 
Male 
67% 
Gender distribution 
0
10
20
30
40
D H P
Gender in each drug 
Female Male
  
53 
 
3. Age Distribution 
 
Descriptive Statistics 
 N Minimum Maximum Mean St. Deviation 
Age 100 35 69 52.85 7.795 
Valid N 
(Listwise) 100     
 
The minimum age encountered in our study is 35 years.  
The maximum age encountered is 69 years.  
Among all three groups, the mean age of the patient is found to be 52 
years. 
 
AGE 
 N Mean Std. Deviation 
D 38 52.89 7.904 
H 38 52.84 7.896 
P 24 52.79 7.791 
Total 100 52.85 7.795 
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Type III 
Sum of 
Squares df
Mean 
Square F Sig.
Sphericity 
Assumed
63656.651 3 21218.884 168.252 .000
Greenhouse-
Geisser
63656.651 1.061 60015.770 168.252 .000
Huynh-Feldt 63656.651 1.066 59724.856 168.252 .0005
Lower-bound 63656.651 1.000 63656.651 168.252 .000
Sphericity 
Assumed
13998.599 111 126.114
Greenhouse-
Geisser
13998.599 39.245 356.701
Huynh-Feldt 13998.599 39.436 354.972
Lower-bound 13998.599 37.000 378.341
Source
CBG
Error(CBG)
4. Drugs and their effect on CBG (capillary blood glucose) 
 Sub- categorical reports 
a) STEROID USED = D (Dexamethasone) 
 
 Mean Std. Deviation N 
CBG AT ADMISSION 105.24 5.410 38 
CBG 6 hrs 141.11 22.576 38 
CBG 12 hrs 162.47 30.642 38 
CBG 48 hrs 137.95 22.262 38 
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Lower 
Bound
Upper 
Bound
2 -35.868* 2.940 .0005 -44.064 -27.673
3 -57.237* 4.271 .0005 -69.144 -45.330
4 -32.711* 2.882 .0005 -40.744 -24.677
1 35.868* 2.940 .000 27.673 44.064
3 -21.368* 1.477 .0005 -25.485 -17.251
4 3.158* .144 .0005 2.757 3.559
1 57.237* 4.271 .000 45.330 69.144
2 21.368* 1.477 .000 17.251 25.485
4 24.526* 1.559 .0005 20.182 28.871
1 32.711* 2.882 .000 24.677 40.744
2 -3.158* .144 .000 -3.559 -2.757
3 -24.526* 1.559 .000 -28.871 -20.182
1
2
3
4
(I) CBG
Mean 
Difference 
(I-J) Std. Error Sig.c
  
Interval for Differencec
 
 
 
 
 
 
 
 
 
 
 
 
Among 38 patients who were administered with Dexamethasone, 
the CBG at 6th, 12th& 48th hour were well above the normal baseline CBG. 
The CBG peaked at the 12th hour after the drug administration. 
b) STEROID USED = H (Hydrocortisone) 
 
 Mean Std. Deviation N 
CBG AT 
ADMISSION 
105.13 8.011 38 
CBG 6 hrs 163.34 20.690 38 
CBG 12 hrs 191.47 22.299 38 
CBG 48 hrs 159.71 20.701 38 
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Lower 
Bound
Upper 
Bound
2 -58.211* 2.333 .0005 -64.713 -51.708
3 -86.342* 2.663 .0005 -93.765 -78.919
4 -54.579* 2.322 .0005 -61.053 -48.105
1 58.211* 2.333 .000 51.708 64.713
3 -28.132* .583 .0005 -29.758 -26.506
4 3.632* .122 .000 3.292 3.971
1 86.342* 2.663 .000 78.919 93.765
2 28.132* .583 .000 26.506 29.758
4 31.763* .629 .0005 30.009 33.518
1 54.579* 2.322 .000 48.105 61.053
2 -3.632* .122 .000 -3.971 -3.292
3 -31.763* .629 .000 -33.518 -30.009
1
2
3
4
(I) CBG
Mean 
Difference 
(I-J) Std. Error Sig.c
  
Interval for Differencec
Type III 
Sum of 
Squares df
Mean 
Square F Sig.
Sphericity 
Assumed
148539.70 3.00 49513.23 837.156 .000
Greenhouse-
Geisser
148539.70 1.08 137574.52 837.156 .000
Huynh-Feldt 148539.70 1.09 136709.27 837.156 .0005
Lower-bound 148539.70 1.00 148539.70 837.156 .000
Sphericity 
Assumed
6565.046 111 59.145
Greenhouse-
Geisser
6565.046 39.949 164.336
Huynh-Feldt 6565.046 40.202 163.302
Lower-bound 6565.046 37.000 177.434
Source
CBG
Error(CBG)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among 38 patients who were administered with Hydrocortisone, the 
CBG at 6th, 12th& 48th hour were well above the normal baseline CBG. 
The CBG peaked at the 12th hour after the drug administration. 
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Type III 
Sum of 
Squares df
Mean 
Square F Sig.
Sphericity 
Assumed
29626.875 3 9875.625 75.165 .000
Greenhouse-
Geisser
29626.875 1.065 27806.870 75.165 .000
Huynh-Feldt 29626.875 1.075 27570.173 75.165 .0005
Lower-bound 29626.875 1.000 29626.875 75.165 .000
Sphericity 
Assumed
9065.625 69 131.386
Greenhouse-
Geisser
9065.625 24.505 369.944
Huynh-Feldt 9065.625 24.716 366.795
Lower-bound 9065.625 23.000 394.158
Source
CBG
Error(CBG)
c) STEROID USED = P (Prednisolone) 
 Mean Std. Deviation N 
CBG AT ADMISSION 103.33 5.362 24 
CBG 6 hrs 134.46 21.875 24 
CBG 12 hrs 152.42 31.661 24 
CBG 48 hrs 131.21 21.405 24 
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Lower 
Bound
Upper 
Bound
2 -31.125* 3.522 .0005 -41.291 -20.959
3 -49.083* 5.569 .0005 -65.157 -33.010
4 -27.875* 3.426 .0005 -37.765 -17.985
1 31.125* 3.522 .000 20.959 41.291
3 -17.958* 2.220 .0005 -24.366 -11.550
4 3.250* .257 .0005 2.508 3.992
1 49.083* 5.569 .000 33.010 65.157
2 17.958* 2.220 .000 11.550 24.366
4 21.208* 2.353 .0005 14.417 27.999
1 27.875* 3.426 .000 17.985 37.765
2 -3.250* .257 .000 -3.992 -2.508
3 -21.208* 2.353 .000 -27.999 -14.417
1
2
3
4
(I) CBG
Mean 
Difference 
(I-J) Std. Error Sig.c
  
Interval for Differencec
 
 
 
 
 
 
 
 
 
 
 
 
 
Among 24 patients who were administered with Prednisolone, the 
CBG at 6th, 12th& 48th hour were well above the normal baseline CBG. 
The CBG peaked at the 12th hour after the drug administration. 
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Prednisolone 
103.33 
134.46 
152.42 
131.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Capillary Blood Glucose level after administration of the drug 
is highest (191.47) with Hydrocortisone > (162.47) with Dexamethasone > 
(152.42) with Prednisolone 
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5. Time at which CBG Peaks with respect to Drug Administration 
a) CBG at Baseline 
 At admission 
D 105.24 
H 105.13 
P 103.33 
 
 
 
  
105.24 105.13 
103.33 
102.00
102.50
103.00
103.50
104.00
104.50
105.00
105.50
D H P
CBG at admission 
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b) CBG at 6th Hour 
 
 CBG 6 hrs 
D 141.11 
H 163.34 
P 134.46 
 
 
 
 
 
 
  
141.11 
163.34 
134.46 
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
180.00
D H P
CBG 6 hrs 
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c) CBG at 12th Hour 
 
 CBG 12 hrs 
D 162.47 
H 191.47 
P 152.42 
 
 
 
 
  
162.47 
191.47 
152.42 
0.00
50.00
100.00
150.00
200.00
250.00
D H P
CBG 12 hrs 
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d) CBG at 48th Hour 
 
 CBG 48 hrs 
D 137.95 
H 159.71 
P 131.21 
 
 
 
  
137.95 
159.71 
131.21 
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
180.00
D H P
CBG 48 hrs 
CBG 48 hrs
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Lower 
Bound
Upper 
Bound
H -22.237* 4.980 .0005 -34.09 -10.38
P 6.647 5.660 .471 -6.82 20.12
D 22.237* 4.980 .0005 10.38 34.09
P 28.884* 5.660 .0005 15.41 42.35
D -6.647 5.660 .471 -20.12 6.82
H -28.884* 5.660 .000 -42.35 -15.41
H -29.000* 6.430 .0005 -44.30 -13.70
P 10.057 7.308 .357 -7.34 27.45
D 29.000* 6.430 .0005 13.70 44.30
P 39.057* 7.308 .000 21.66 56.45
D -10.057 7.308 .357 -27.45 7.34
H -39.057* 7.308 .000 -56.45 -21.66
H -21.763* 4.927 .0005 -33.49 -10.04
P 6.739 5.599 .454 -6.59 20.07
D 21.763* 4.927 .000 10.04 33.49
P 28.502* 5.599 .0005 15.18 41.83
D -6.739 5.599 .454 -20.07 6.59
H -28.502* 5.599 .000 -41.83 -15.18
CBG 12 hrs D
H
P
CBG 48 hrs D
H
P
Dependent Variable
Mean 
Difference 
(I-J) Std. Error Sig.
95% Co de ce 
Interval
CBG 6 hrs D
H
P
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 D H P 
At admission 105.24 105.13 103.33 
6 hrs 141.11 163.34 134.46 
12 hrs 162.47 191.47 152.42 
48 hrs 137.95 159.71 131.21 
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The Capillary Blood Glucose peaks at the 12th hour after 
administration of any of the three drugs namely Dexamethasone, 
Hydrocortisone & Prednisolone. 
 
 
 
  
0.00
50.00
100.00
150.00
200.00
250.00
At admission 6 hrs 12 hrs 48 hrs
CBG trend 
D H P
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6. Risk Factors for Steroid induced Hyperglycemia 
 The risk factors are: 
 
 AGE 
 BMI 
 WAIST CIRCUMFERENCE 
 BLOOD PRESSURE 
 FASTING LIPID PROFILE (serum cholesterol & triglyceride) 
 BASELINE HbA1C 
 
a) Dexamethasone 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
B Std. Error Beta 
  
(Constant) -50.700 55.999   -.905 .371 
HbA1C -40.044 19.410 -.401 -2.063 .047 
SYS 3.296 .489 1.309 6.738 .0005 
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Standardiz
ed 
Coefficient
s
B Std. Error Beta
(Constant) -18.837 182.750 -.103 .919
HbA1C -27.176 27.363 -.272 -.993 .329
SYS 3.308 .621 1.313 5.329 .000
DIAS 1.342 1.372 .230 .979 .336
BMI 2.162 2.629 .258 .822 .417
WC -.398 .425 -.108 -.936 .357
SERUM CHO -1.297 1.675 -.580 -.774 .445
TGL .128 .996 .083 .128 .899
(Constant) -39.598 83.343 -.475 .638
HbA1C -27.690 26.634 -.277 -1.040 .307
SYS 3.302 .609 1.311 5.423 .000
DIAS 1.430 1.171 .245 1.221 .231
BMI 2.136 2.579 .254 .828 .414
WC -.402 .417 -.109 -.965 .342
SERUM CHO -1.117 .904 -.500 -1.236 .226
(Constant) -80.686 66.642 -1.211 .235
HbA1C -24.266 26.182 -.243 -.927 .361
SYS 3.493 .560 1.387 6.235 .000
DIAS .817 .903 .140 .904 .373
WC -.229 .359 -.062 -.638 .528
SERUM CHO -.692 .741 -.310 -.935 .357
(Constant) -84.263 65.805 -1.280 .209
HbA1C -24.694 25.937 -.247 -.952 .348
SYS 3.399 .536 1.350 6.347 .000
DIAS .834 .895 .143 .933 .358
SERUM CHO -.714 .733 -.319 -.973 .337
(Constant) -54.343 57.347 -.948 .350
HbA1C -34.595 23.620 -.346 -1.465 .152
SYS 3.380 .534 1.342 6.327 .000
SERUM CHO -.201 .485 -.090 -.415 .680
(Constant) -50.700 55.999 -.905 .371
HbA1C -40.044 19.410 -.401 -2.063 .047
SYS 3.296 .489 1.309 6.738 .000
1
2
3
4
5
6
Model
Unstandardized 
Coefficients
t Sig.
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b) Hydrocortisone 
  Standardiz
ed 
Coefficient
s
B Std. Error Beta
(Constant) -233.495 169.785 -1.375 .179
HbA1C 7.837 13.823 .121 .567 .575
SYS 1.482 .634 .911 2.336 .026
DIAS 2.531 1.258 .553 2.012 .053
BMI -2.142 2.581 -.388 -.830 .413
WC .639 .321 .244 1.989 .056
SERUM CHO .208 1.403 .139 .148 .883
TGL -.629 .752 -.612 -.836 .410
(Constant) -212.821 95.324 -2.233 .033
HbA1C 8.566 12.715 .132 .674 .506
SYS 1.493 .620 .917 2.408 .022
DIAS 2.481 1.193 .542 2.080 .046
BMI -1.864 1.742 -.338 -1.070 .293
WC .649 .308 .248 2.103 .044
TGL -.547 .503 -.533 -1.087 .285
(Constant) -174.262 75.574 -2.306 .028
SYS 1.488 .615 .914 2.421 .021
DIAS 2.403 1.177 .525 2.042 .050
BMI -1.406 1.590 -.255 -.884 .383
WC .642 .306 .246 2.100 .044
TGL -.484 .490 -.472 -.988 .330
(Constant) -168.845 75.076 -2.249 .031
SYS 1.277 .565 .785 2.262 .030
DIAS 2.503 1.168 .547 2.144 .040
WC .610 .303 .233 2.016 .052
TGL -.617 .465 -.601 -1.328 .193
(Constant) -83.220 38.847 -2.142 .039
SYS .644 .305 .396 2.108 .042
DIAS 1.559 .937 .341 1.665 .105
WC .578 .305 .221 1.896 .067
(Constant) -26.947 19.619 -1.374 .178
SYS 1.062 .178 .652 5.953 .000
WC .781 .286 .299 2.728 .010
3
4
5
6
Model
Unstandardized 
Coefficients
t Sig.
1
2
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Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
B Std. Error Beta 
  
(Constant) -26.947 19.619   -1.374 .178 
SYS 1.062 .178 .652 5.953 .0005 
WC .781 .286 .299 2.728 .010 
 
 
 
c)Prednisolone 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
B Std. Error Beta 
  
(Constant) -353.440 45.329   -7.797 .0005 
HbA1C 71.864 11.483 .715 6.258 .0005 
WC .939 .390 .275 2.409 .025 
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Standardiz
ed 
Coefficient
s
B Std. Error Beta
(Constant) -521.029 279.869 -1.862 .081
HbA1C 59.653 41.450 .593 1.439 .169
SYS -.130 1.118 -.046 -.116 .909
DIAS 1.972 2.951 .331 .668 .514
BMI .405 5.600 .046 .072 .943
WC .793 .787 .232 1.008 .329
SERUM CHO 1.171 1.728 .549 .678 .508
TGL -1.029 1.541 -.700 -.667 .514
(Constant) -523.072 270.170 -1.936 .070
HbA1C 61.357 33.087 .610 1.854 .081
SYS -.105 1.032 -.037 -.102 .920
DIAS 1.880 2.581 .315 .728 .476
WC .816 .699 .239 1.168 .259
SERUM CHO 1.158 1.667 .542 .695 .497
TGL -.976 1.316 -.664 -.741 .469
(Constant) -508.207 220.929 -2.300 .034
HbA1C 59.424 26.334 .591 2.257 .037
DIAS 1.745 2.152 .292 .811 .428
WC .792 .640 .232 1.238 .232
SERUM CHO 1.102 1.532 .516 .720 .481
TGL -.923 1.176 -.628 -.785 .443
(Constant) -419.768 181.267 -2.316 .032
HbA1C 67.302 23.646 .669 2.846 .010
DIAS 1.487 2.095 .249 .710 .486
WC 1.042 .530 .305 1.965 .064
TGL -.309 .800 -.210 -.387 .703
(Constant) -352.049 45.692 -7.705 .000
HbA1C 61.206 17.242 .609 3.550 .002
DIAS .763 .915 .128 .834 .414
WC .909 .394 .266 2.304 .032
(Constant) -353.440 45.329 -7.797 .000
HbA1C 71.864 11.483 .715 6.258 .000
WC .939 .390 .275 2.409 .025
3
4
5
6
Model
Unstandardized 
Coefficients
t Sig.
1
2
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AGE AS THE RISK FACTOR 
 
P - Value ** Highly Significant at P ≤ .01 
     
P - Value * Significant at 0.01 < P ≤ .05 
     
P -Value # No Significant at P >.05 
 
Dexamethasone 
 
  
AGE
CBG 12 
hrs
Pearson 
Correlatio
n
1 .379*
Sig. (2-
tailed)
.019
N 38 38
Pearson 
Correlatio
n
.379* 1
Sig. (2-
tailed)
.019
N 38 38
AGE
CBG 12 
hrs
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Hydrocortisone 
 
 
 
 
 
 
 
 
 
Prednisolone 
 
  
AGE
CBG 12 
hrs
Pearson 
Correlatio
n
1 .338*
Sig. (2-
tailed)
.038
N 38 38
Pearson 
Correlatio
n
.338* 1
Sig. (2-
tailed)
.038
N 38 38
AGE
CBG 12 
hrs
AGE
CBG 12 
hrs
Pearson 
Correlatio
n
1 .289
Sig. (2-
tailed)
.171
N 24 24
Pearson 
Correlatio
n
.289 1
Sig. (2-
tailed)
.171
N 24 24
CBG 12 
hrs
AGE
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DISCUSSION 
Corticosteroid plays a significant role in our day to day practice. 
The aim of this work is to understand in depth about the most 
common adverse effect of corticosteroid which is hyperglycemia. 
As hyperglycemia is one among the most important factors that 
increases  cardio-vascular risk, this study is taken up to mitigate the risk. 
Through this study the following points have become evident: 
1. There is rise in capillary blood glucose level after administration of 
steroid during all the three different times (6, 12 & 48 hours) and 
with respect to all the three different drugs given to the patient for 
their exacerbation. Thus the occurrence of hyperglycemia within 48 
hours in patients started on corticosteroid therapy is proven. 
2. The Capillary Blood Glucose level after administration of the drug 
is highest 191.47) with Hydrocortisone > (162.47) with 
Dexamethasone > (152.42) with Prednisolone. 
3. So the risk of (dys) hyperglycemia is highest with Hydrocortisone 
(short acting) when compared with other two drugs (long acting). 
4. Thus steroid induced hyperglycemia is more with parentral steroids 
than oral forms. 
5. The Capillary Blood Glucose peaks at the 12th hour after 
administration of any of the three drugs namely Dexamethasone, 
Hydrocortisone & Prednisolone. 
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Thus traditional way of testing for fasting and post-prandial blood 
sugar to see for dysglycemia is no longer useful in case of steroid induced 
hyperglycemia. Many a times it has been told in other studies  that it is the 
post-prandial hyperglycemia that predominates than the fasting 
hyperglycemia in case of steroid induced hyperglycemia.  
In my study there are 6 different risk factors that have been taken 
and analysed especially with the hyperglycemia that has occurred at 12th 
hour of administration of any of the three corticosteroids. 
In my study it is found that  
1. HbA1C& Systolic BP has significant correlation for 
Dexamethasone. 
2. Systolic BP & Waist Circumference has significant correlation for 
Hydrocortisone. 
3. HbA1C& Waist Circumference has significant correlation for 
Prednisolone. 
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CONCLUSION 
 
Similar to the other studies which shows that the glycemic rise 
related to steroid therapy usually begins 4 hours after the dose and usually 
persists for up to 16 hours, in my study also CBG level starts rising at 6th 
hour, peaks at 12th hour & starts to decline by 48th hour after 
administration of steroid therapy.  
Thus a better understanding of the glycemic effect of various steroid 
will allow the development of a specific treatment strategy for steroid-
induced hyperglycemia that targets the time of day during which 
hyperglycemia predominates. 
Current conventional strategies in treating hyperglycemia may 
inadequately treat postprandial hyperglycemia that occurs after steroid 
therapy, and use of long-acting basal insulin may precipitate nocturnal 
hypoglycemia. 
So short acting steroid – Hydrocortisone with highest rise in CBG at 
all three times after its administration is to be avoided unless the clinical 
condition demands. 
Oral Prednisolone is comparatively safer drug with less side effect                           
(hyperglycemia) profile & ease of administration. But oral route not useful 
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in patients not able to tolerate oral drugs due to vomiting & especially at 
acute exacerbations. 
It is also evident that increased waist circumference, BMI, baseline 
HbA1C, blood pressure are all associated significantly withsteroid induced 
hyperglycemia. 
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APPENDIX 2  
PROFORMA 
Name:                                                     Age/sex: 
Address:                                                       IPNO: 
Diagnosis: 
BMI: 
Waist circumference: 
Blood Pressure: 
Questionnarie: 
Previous history of  
diabetes mellitus, 
systemic hypertension, 
dyslipidemia, 
steroid intake, 
smoking& alcoholism. 
INVESTIGATIONS: 
- Pre therapy Capillary blood glucose level 
- Pre therapy HbA1c 
- Capillary blood glucose at 6 hours of steroid administration 
- Capillary blood glucose at 12 hours of steroid administration  
- Capillary blood glucose at 48 hours of steroid administration  
- Fasting lipid profile 
TYPE & DOSE of STEROID used. 
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ETHICAL COMMITTEE APPROVAL 
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KEY TO MASTER CHART 
 
CBG AT 0  - Capillary blood glucose at the time of admission 
CBG AT 6  - Capillary blood glucose at 6 hours after the  
     administration of steroid 
CBG AT 12  - Capillary blood glucose at 12 hours after the 
     administration of steroid 
CBG AT 48  - Capillary blood glucose at 48 hours after the 
     administration of steroid 
BP mmHg  - blood pressure in mmHg 
BMI   - body mass index 
WC   - waist circumference 
S. CHL  - serum cholesterol 
S. TGL  - serum triglyceride 
HbA1C  - glycated hemoglobin 
STEROID  - steroid used in the patient 
            P    - PREDNISOLONE 
            H   - HYDROCORTISONE 
            D   - DEXAMETHASONE 
SEX – M   - male 
 F    - female 
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